Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
”Myeloma Paper of the Day:
Study of cumulative effect of cytogenetic abnormalities on outcomes of myeloma pts w/ del(17p) getting ASCT finds co-occurring t(4;14)(HR 1.38), ISS stage III disease (HR 1.87) and PR or less (HR 1.40) are adverse features.”
Title: The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022
Authors: Claire Comerford, Patrick J. Hayden, Diderik-Jan Eikema, Linda Koster, Sandra Sauer, Annoek Broers, Neil Rabin, Jean Noel Bastie, Tobias Gedde-Dahl, Luisa Giaccone, Deborah Richardson, Kristina Carlson, Britta Besemer, Jean-Marc Schiano de Colella, Robert Zeiser, Laure Vincent, Thomas Pabst, Anne Cairoli, Christine Schuermans, Monica Poiani, Kavita Raj, Joanna Drozd-Sokolowska, Laurent Garderet, Inas El Najjar, Meral Beksac, Donal P. McLornan
You can read the full article on British Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
